Patents by Inventor Stephen W Kaldor

Stephen W Kaldor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAPK/ERK Kinase Inhibitors
    Publication number: 20110190261
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(pyrimidinylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Application
    Filed: April 7, 2011
    Publication date: August 4, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Qing Dong, Stephen W. Kaldor
  • Substituted 1,3-dialkyl-2,4-dioxo-6-(pyridylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
    Patent number: 7943626
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Grant
    Filed: January 5, 2010
    Date of Patent: May 17, 2011
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Stephen W. Kaldor
  • POLO-LIKE KINASE INHIBITORS
    Publication number: 20110082111
    Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: December 7, 2010
    Publication date: April 7, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. KALDOR, Andre A. KIRYANOV, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
  • MAPK/ERK KINASE INHIBITORS
    Publication number: 20110065733
    Abstract: Compounds of the following formula are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: October 7, 2010
    Publication date: March 17, 2011
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Qing Dong, Stephen W. Kaldor
  • Dipeptidyl peptidase inhibitors
    Patent number: 7790736
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7790734
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: September 2, 2004
    Date of Patent: September 7, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Sheldon X. Cao, Jun Feng, Stephen L. Gwaltney, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Xiao-Yi Xiao, Zhiyuan Zhang
  • RENIN INHIBITORS
    Publication number: 20100210635
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with Renin that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: March 23, 2007
    Publication date: August 19, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Benjamin Jones, Andre A. Kiryanov, Stephen W. Kaldor
  • MAPK/ERK KINASE INHIBITORS
    Publication number: 20100204471
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.
    Type: Application
    Filed: October 22, 2007
    Publication date: August 12, 2010
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Qing Dong, Victoria Feher, Stephen W. Kaldor, Naoki Tomita
  • MAPK/ERK KINASE INHIBITORS
    Publication number: 20100130518
    Abstract: Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: December 18, 2007
    Publication date: May 27, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Qing Dong, Xianchang Gong, Stephen W. Kaldor, Toufike Kanouni, Nicholas Scorah, Michael B. Wallace, Feng Zhou
  • Dipeptidyl peptidase inhibitors
    Patent number: 7723344
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: May 25, 2010
    Assignee: Takeda San Diego, Inc.
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • MAPK/ERK Kinase Inhibitors
    Publication number: 20100113413
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Application
    Filed: January 5, 2010
    Publication date: May 6, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Qing Dong, Stephen W. Kaldor
  • Mitotic Kinase Inhibitors
    Publication number: 20100093767
    Abstract: The invention relates to inhibitors of enzymes that disrupt the assembly and function of the mitotic spindle, compositions comprising the inhibitors of Formula (I), kits and articles of manufacture comprising the inhibitors and inhibitor compositions, and methods of using the inhibitors and inhibitor compositions. The inhibitors and inhibitor compositions are useful for treating, preventing or modulating diseases in which mitotic kinesins, including kinesin-like spindle protein (KSP), may be involved; symptoms of such diseases; or the effect of other physiological events mediated by mitotic kinesins, including KSP.
    Type: Application
    Filed: December 2, 2005
    Publication date: April 15, 2010
    Applicant: TAKEDA SAN DIEGO, INC.
    Inventors: Jerome C. Bressi, Andrew John Jennings, Stephen W. Kaldor, Lily Kwok, Clifford D. Mol, Jeffrey A. Stafford
  • Substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acid inhibitors of MAPK/ERK kinase
    Patent number: 7696218
    Abstract: Compounds of the substituted 1,3-dialkyl-2,4-dioxo-6-(arylamino)-1,2,3,4-tetrahydropyrimidine-5-hydroxamic acids, show below: wherein the variables are as defined herein, and pharmaceutical compositions thereof, are provided for use as inhibitors of with MEK kinase.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: April 13, 2010
    Assignee: Takeda San Diego, Inc.
    Inventors: Qing Dong, Stephen W. Kaldor
  • Dipeptidyl peptidase inhibitors
    Patent number: 7687625
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 protease that comprise a compound comprising the formula: wherein Q is selected from the group of CO, SO, SO2, or C?NR9; and R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: March 30, 2010
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang
  • POLO-LIKE KINASE INHIBITORS
    Publication number: 20100075973
    Abstract: The present invention provides PLK inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using the compounds.
    Type: Application
    Filed: August 20, 2009
    Publication date: March 25, 2010
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Sheldon X. Cao, Takashi Ichikawa, Andre A. Kiryanov, Christopher McBride, Srinivasa Reddy Natala, Stephen W. Kaldor, Jeffrey A. Stafford
  • Histone deacetylase inhibitors
    Patent number: 7642275
    Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with histone deacetylases (HDACs) that comprise a compound of the formulae: wherein the variables are as defined herein.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: January 5, 2010
    Assignee: Takeda San Diego, Inc.
    Inventors: Jerome C. Bressi, Jason W. Brown, Robert J. Skene, Jeffrey A. Stafford, Phong H. Vu, Anthony R. Gangloff, Andrew J. Jennings, Stephen W. Kaldor
  • POLO-LIKE KINASE INHIBITORS
    Publication number: 20090291938
    Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: November 19, 2008
    Publication date: November 26, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. Kaldor, Andre A. Kiryanov, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
  • POLO-LIKE KINASE INHIBITORS
    Publication number: 20090281092
    Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
    Type: Application
    Filed: September 24, 2008
    Publication date: November 12, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. Kaldor, Andre A. Kiryanov, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
  • Dipeptidyl peptidase inhibitors
    Patent number: 7579357
    Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV inhibitors comprising Formula I: wherein the substituents are as described herein.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: August 25, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, II, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhlyuan Zhang
  • Dipeptidyl peptidase inhibitors
    Patent number: 7550590
    Abstract: Compounds, pharmaceuticals, kits, and methods are provided for use with DPP-IV and other S9 protease that comprise a compound comprising the formula: wherein Q is selected from the group of CO, SO, SO2, or C?NR9; and R1, R2, R3 and R4 are as defined herein.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: June 23, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jun Feng, Stephen L. Gwaltney, Stephen W. Kaldor, Jeffrey A. Stafford, Michael B. Wallace, Zhiyuan Zhang